Early results of AG-221, an inhibitor of mutant IDH2, showed that from 48 patients with advanced AML/MDS with an IDH2 mutation, 20 patients had evidence of an objective response (eight complete remissions) (see Table 2) [146,147]. Here, IDH2 is linked to myelodysplastic syndrome.